(Q37951770)

25 August 2017

0 references

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis (English)

1 reference

25 August 2017

0 references

1 reference

irritable bowel syndrome

1 reference

Stacy B Menees

1

1 reference

25 August 2017

Monthira Maneerattannaporn

series ordinal

2

1 reference

25 August 2017

Hyungjin Myra Kim

series ordinal

3

1 reference

25 August 2017

William D Chey

series ordinal

4

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 November 2011

1 reference

The American Journal of Gastroenterology

25 August 2017

1 reference

25 August 2017

107

1 reference

25 August 2017

1

1 reference

25 August 2017

28-35; quiz 36

1 reference

Functional bowel disorders

25 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

An evidence-based position statement on the management of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Management of the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Is there a SERT-ain association with IBS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Early life risk factors that contribute to irritable bowel syndrome in adults: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 2. Motility of the small bowel, esophagus, stomach, and gall-bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Altered rectal perception is a biological marker of patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Brain imaging of visceral functions in healthy volunteers and IBS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Reduced brainstem inhibition during anticipated pelvic visceral pain correlates with enhanced brain response to the visceral stimulus in women with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Abnormal breath testing in IBS: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Small intestinal bacterial overgrowth in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome--a longitudinal study in IBS and control subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Food: the forgotten factor in the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Rifaximin--a novel antimicrobial for enteric infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Effects of antimicrobial therapy on faecal bulking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Gender differences in treatment response to sertraline versus imipramine in chronic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.355

21 January 2018

Identifiers

DOI

10.1038/AJG.2011.355

1 reference

25 August 2017

1 reference